Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Novartis has decided to exit antibacterial and antiviral research. About 140 related jobs are being eliminated in Emeryville, Calif.; about 150 jobs will remain in the San Francisco Bay Area at the Novartis Institute for Tropical Diseases and at departments that support efforts focused on difficult targets. The firm says it is talking to other companies about out-licensing its antibiotic programs. They include LYS228, a compound that is being tested in clinical trials for its ability to kill Gram-negative bacteria.
This article has been sent to the following recipient: